Dr. Whitcomb's research group is organized to determine the mechanism of complex disorders including acute pancreatitis, chronic pancreatitis and pancreatic cancer. This has led to the publication of over two hundred peer reviewed research manuscripts, multiple reviews, book chapters and the editing of 8 books. In addition, he has mentored over three dozen trainees at all levels of education. Dr. Whitcomb has been funded to study pancreatic physiology, neurohormonal control mechanisms, alcohol toxicity, molecular biology, biomarkers, gene expression and genetic studies, including the multicenter North American Pancreatitis 2 (NAPS2) study and the Study of Nutrition in Acute Pancreatitis Study (SNAP). He co-leads two prospective cohort studies at the University of Pittsburgh; Pancreatic Adenocarcinoma Gene Environment Risk (PAGER) study, and the Pancreatitis-associated Risk Of Organ Failure (PROOF) study. Due to his administrative responsibilities, Dr. Whitcomb has consolidated his physiology, molecular biology and genetics research laboratories to focus on high-throughput genetics and biomarker center for translational research. In concert with this effort Dr. Whitcomb is developing personalized medicine integrating clinical data, genetics and biomarkers with statistical and mathematical models of complex diseases. This includes pancreatic duct cells, gallbladder physiology and acute pancreatitis. Additional, and more complex models are being developed, which will be critical in synchronizing complex data sets and predicting the effects of therapeutic interventions in simulated patient care.